cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Dr. dr. Puspa Wardhani, SpPK
Contact Email
admin@indonesianjournalofclinicalpathology.org
Phone
+6285733220600
Journal Mail Official
majalah.jicp@yahoo.com
Editorial Address
Laboratorium Patologi Klinik RSUD Dr. Soetomo Jl. Mayjend. Prof. Dr. Moestopo 6-8 Surabaya
Location
Kota adm. jakarta selatan,
Dki jakarta
INDONESIA
Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML)
Published by Perhimpunan Dokter Spesialis Patologi Klinik Indonesia
ISSN : 08544263     EISSN : 24774685     DOI : https://dx.doi.org/10.24293
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience
Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) is a journal published by “Association of Clinical Pathologist” professional association. This journal displays articles in the Clinical Pathology and Medical Laboratory scope. Clinical Pathology has a couple of subdivisions, namely: Clinical Chemistry, Hematology, Immunology and Serology, Microbiology and Infectious Disease, Hepatology, Cardiovascular, Endocrinology, Blood Transfusion, Nephrology, and Molecular Biology. Scientific articles of these topics, mainly emphasize on the laboratory examinations, pathophysiology, and pathogenesis in a disease.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 23 Documents
 1   2   3 
Search results for , issue "Vol 29, No 1 (2022)" : 23 Documents clear
Analysis of NLR, HDL, and Hs-Troponin I as A Diagnostic Marker in STEMI and NSTEMI Patients Yunianingsih Selanno; Darmawaty ER; Sulina Yanti Wibawa; Agus Alim Abdullah
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 29, No 1 (2022)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v29i1.2083

Abstract

The limitations of health facilities in diagnosing AMI, especially in remote areas require an easy and inexpensive examination such as Neutrophil Lymphocyte Ratio (NLR) and High-Density Lipoprotein (HDL), which have a positive correlation with hs-Troponin I. The purpose of this study was to analyze the value of NLR, HDL, and hs-Troponin I as diagnostic markers in STEMI and NSTEMI patients. This retrospective study used medical record data for 152 STEMI patients and 93 NSTEMI patients from January to December 2020 at Dr. Wahidin Sudirohusodo. The NLR value was based on the results of routine blood tests using Sysmex XN-10, the results of HDL examinations using the Bio Majesty JCA-BM9010/c instrument, and the results of the hs-Troponin I examination using the Vidas instrument. Statistical tests using the MannWhitney test, the diagnostic value of NLR, and hs-Troponin I was analyzed by ROC to obtain the cut-off. The test result is significant if p <0.05. The sample consisted of 152 samples of STEMI patients and 93 NSTEMI patients. The NLR value in STEMI patients was significantly different from NSTEMI patients (p <0.001), HDL levels were not significantly different in STEMI and NSTEMI patients (p=0.475), while hs-Troponin I levels were significantly higher in STEMI patients than NSTEMI (p <0.001). The ROC curve showed the sensitivity and specificity of NLR, namely 64% and 70% at the cut-off of 4.32, and the sensitivity and specificity of hs-Troponin I was 78% and 60% at the cut-off of 910.5 ng /L. The NLR and hs-Troponin I values was increased in STEMI patients compared to NSTEMI due to the increased inflammatory response and the higher risk of damage to the myocardium. The coordinates of the NLR ROC curve show a cut-off of 4.32 and hs-Troponin I 910.5 ng/L provides optimal sensitivity and specificity. The conclusion of this study is NLR and hs-Troponin I can be used as diagnostic markers in STEMI and NTEMI patients with a cut-off value of NLR 4.32 and hs-Troponin I 910.5 ng/L.
S-RBD IgG Response After Second Dose of CoronaVac; Prospective Study on Health Workers Cynthia Ayu Permatasari; Jusak Nugraha; Munawaroh Fitriah
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 29, No 1 (2022)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v29i1.1981

Abstract

COVID-19 infection causes severe acute respiratory syndrome and requires immediate action. Therefore, developing safe vaccine efficacy and new therapies has become a global priority for achieving herd immunity. Vaccination is expected to form specific antibodies against the SARS-CoV-2 spike protein that can neutralize the virus, thus preventing it from binding to its specific receptor (ACE 2 receptor). This study aimed to analyze the kinetics of antibody response to the CoronaVac vaccine after administration of the second dose vaccine. An observational analytic study with a prospective cohort approach was conducted from January to November 2021 at Dr. Soetomo General Academic Hospital, Surabaya. Two hundred fifty specimens from 50 health workers who met the inclusion criteria were measured for S-RBD IgG levels using the indirect chemiluminescence immunoassay method on the Snibe Maglumi® device. The SARS-CoV-2 S-RBD IgG levels were measured five times, such as before vaccination (day 0) and day 14, day 28, month 3, and month 6 after vaccination of the second dose of CoronaVac. The median (min-max) of S-RBD IgG levels before and after vaccination of the second dose on day 14, day 28, month 3, and month 6 were 0.43 (0.43–4.07); 109,25 (30.71–1619,42); 136,46 (19.38–725,28); 26.56 (7.64–158,65); 13.11 (0.59–8666,00) BAU/mL, respectively. There was a significant difference in S-RBD IgG levels at six months post-vaccination between the group with COVID-19 infection and those without COVID-19 disease (p < 0.001). Vaccination of the second dose of CoronaVac resulted in antibody formation; however, there was a trend of decreasing humoral immunity in the 3rd month after the second dose of CoronaVac vaccination in healthy individuals.
The Correlation between RDW, PDW, and NLR with the SOFA Score in Septic Patients Linda Mayliana Kusumaningrum Nurtadjudin; Irda Handayani; Agus Alim Abdullah; Mansyur Arif
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 29, No 1 (2022)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v29i1.1960

Abstract

Sepsis is one of the main causes of mortality in the intensive care unit. The SOFA score is used to assess organ dysfunction. There are several markers of sepsis such as the combination of RDW, PDW, and NLR to help predict the outcome of sepsis. To determine the role of RDW, PDW, and NLR associated with SOFA scores as prognostic markers in sepsis. A retrospective study with a cross-sectional approach has been conducted using secondary data from the medical records of sepsis patients from January 2018 to December 31, 2020, who met the inclusion criteria and were admitted to the ICU of Dr. Wahidin Sudirohusodo Hospital, Makassar. The sample size was 109 people consisting of 62 (56.9%) males and 47 (43.1%) females. The highest age range is 56–65 years (37.6%). A total of 97 people (89%) died and 12 (11%) improved. There is a positive correlation between changes in RDW and changes in SOFA scores (p=0.031), there is a positive correlation between changes in PDW and changes in SOFA scores (p=0.000), and there is a positive correlation between changes in NLR and changes in SOFA scores (p=0.000). The increase of RDW caused by systemic inflammation can predict disease progression. The state of increased proinflammatory cytokines inhibits the proliferation and maturation of erythrocytes; hence, it causes an increase in RDW. The acceleration of platelet destruction due to the suppression of cytokines in the bone marrow increases PDW. The increase in NLR occurs due to the rise in the inflammatory response, which results in suppressed cellular immunity. RDW, PDW, and NLR are positively correlated with changes in SOFA scores. PDW and NLR have a significant correlation with the outcome. RDW, PDW, and NLR can be used as prognostic markers in septic patients

Page 3 of 3 | Total Record : 23

 1   2   3 

Filter by Year

2022 2022


Reset
Filter By Issues
All Issue Vol. 32 No. 1 (2025) Vol. 31 No. 3 (2025) Vol. 31 No. 2 (2025) Vol. 31 No. 1 (2024) Vol. 30 No. 3 (2024) Vol. 30 No. 2 (2024) Vol. 30 No. 1 (2023) Vol. 29 No. 3 (2023) Vol. 29 No. 2 (2023) Vol. 29 No. 1 (2022) Vol 29, No 1 (2022) Vol 28, No 3 (2022) Vol. 28 No. 3 (2022) Vol. 28 No. 2 (2022) Vol 28, No 2 (2022) Vol. 28 No. 1 (2021) Vol 28, No 1 (2021) Vol. 27 No. 3 (2021) Vol 27, No 3 (2021) Vol 27, No 2 (2021) Vol. 27 No. 2 (2021) Vol. 27 No. 1 (2020) Vol 27, No 1 (2020) Vol. 26 No. 3 (2020) Vol 26, No 3 (2020) Vol 26, No 2 (2020) Vol. 26 No. 2 (2020) Vol 26, No 1 (2019) Vol. 26 No. 1 (2019) Vol. 25 No. 3 (2019) Vol 25, No 3 (2019) Vol. 25 No. 2 (2019) Vol 25, No 2 (2019) Vol 25, No 1 (2018) Vol. 25 No. 1 (2018) Vol 24, No 3 (2018) Vol. 24 No. 3 (2018) Vol. 24 No. 2 (2018) Vol 24, No 2 (2018) Vol 24, No 1 (2017) Vol. 24 No. 1 (2017) Vol. 23 No. 3 (2017) Vol 23, No 3 (2017) Vol. 23 No. 2 (2017) Vol 23, No 2 (2017) Vol 23, No 1 (2016) Vol 22, No 3 (2016) Vol 22, No 2 (2016) Vol 22, No 1 (2015) Vol 21, No 3 (2015) Vol 21, No 2 (2015) Vol 21, No 1 (2014) Vol 20, No 3 (2014) Vol 20, No 2 (2014) Vol 20, No 1 (2013) Vol 19, No 3 (2013) Vol 19, No 2 (2013) Vol 19, No 1 (2012) Vol. 19 No. 1 (2012) Vol 18, No 3 (2012) Vol. 18 No. 3 (2012) Vol 18, No 2 (2012) Vol 18, No 1 (2011) Vol. 18 No. 1 (2011) Vol 17, No 3 (2011) Vol 17, No 2 (2011) Vol 17, No 1 (2010) Vol 16, No 3 (2010) Vol 16, No 2 (2010) Vol 16, No 1 (2009) Vol 15, No 3 (2009) Vol 15, No 2 (2009) Vol 15, No 1 (2008) Vol 14, No 3 (2008) Vol 14, No 2 (2008) Vol 14, No 1 (2007) Vol 13, No 3 (2007) Vol 13, No 2 (2007) Vol 13, No 1 (2006) Vol 12, No 3 (2006) Vol 12, No 2 (2005) Vol 12, No 1 (2005) More Issue